Voyager Therapeutics Inc. (VYGR)
Voyager Therapeutics Statistics
Share Statistics
Voyager Therapeutics has 55.21M shares outstanding. The number of shares has increased by 1.5% in one year.
| Shares Outstanding | 55.21M |
| Shares Change (YoY) | 1.5% |
| Shares Change (QoQ) | 1.06% |
| Owned by Institutions (%) | 59.65% |
| Shares Floating | 44.87M |
| Failed to Deliver (FTD) Shares | 1.26K |
| FTD / Avg. Volume | 0.35% |
Short Selling Information
The latest short interest is 2.55M, so 4.68% of the outstanding shares have been sold short.
| Short Interest | 2.55M |
| Short % of Shares Out | 4.68% |
| Short % of Float | 5.66% |
| Short Ratio (days to cover) | 6.5 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -3.71. Voyager Therapeutics's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -3.71 |
| PS Ratio | 4.09 |
| Forward PS | 2.8 |
| PB Ratio | 1.09 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Voyager Therapeutics Inc. has an Enterprise Value (EV) of 314.59M.
| EV / Earnings | -4.84 |
| EV / Sales | 3.93 |
| EV / EBITDA | -3.78 |
| EV / EBIT | -3.78 |
| EV / FCF | -16.71 |
Financial Position
The company has a current ratio of 5.56, with a Debt / Equity ratio of undefined.
| Current Ratio | 5.56 |
| Quick Ratio | 5.56 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | 12.73 |
| Cash Flow / Debt | -0.35 |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -24.5%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -24.5% |
| Revenue Per Employee | $465,122.09 |
| Profits Per Employee | $-377,918.6 |
| Employee Count | 172 |
| Asset Turnover | 0.2 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 665K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -68.03% in the last 52 weeks. The beta is 0.99, so Voyager Therapeutics's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | -68.03% |
| 50-Day Moving Average | 4.49 |
| 200-Day Moving Average | 6.28 |
| Relative Strength Index (RSI) | 28.64 |
| Average Volume (20 Days) | 361.5K |
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 80M and earned -65M in profits. Earnings per share was -1.13.
| Revenue | 80M |
| Gross Profit | 80M |
| Operating Income | -83.29M |
| Net Income | -65M |
| EBITDA | -83.29M |
| EBIT | -83.29M |
| Earnings Per Share (EPS) | -1.13 |
Balance Sheet
The company has 71.37M in cash and 43.73M in debt, giving a net cash position of 27.64M.
| Cash & Cash Equivalents | 71.37M |
| Total Debt | 43.73M |
| Net Cash | 27.64M |
| Retained Earnings | -326.18M |
| Total Assets | 393.05M |
| Working Capital | 227.02M |
Cash Flow
In the last 12 months, operating cash flow was -15.31M and capital expenditures -3.52M, giving a free cash flow of -18.83M.
| Operating Cash Flow | -15.31M |
| Capital Expenditures | -3.52M |
| Free Cash Flow | -18.83M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 100%, with operating and profit margins of -104.11% and -81.25%.
| Gross Margin | 100% |
| Operating Margin | -104.11% |
| Pretax Margin | -80.42% |
| Profit Margin | -81.25% |
| EBITDA Margin | -104.11% |
| EBIT Margin | -104.11% |
| FCF Margin | -23.54% |
Dividends & Yields
VYGR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -33.53% |
| FCF Yield | -10.12% |
Analyst Forecast
The average price target for VYGR is $12, which is 256.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 256.1% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 0.36 |
| Piotroski F-Score | 3 |